The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Mexican President Claudia Sheinbaum expressed her resolve to maintain composure while awaiting the United States' decision ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

The imposition of United States tariffs on Mexican products would cause shortages and price increases in several sectors ...

KBRA assigns preliminary ratings to four classes of notes issued by Oportun Funding Trust 2025-1 ("Oportun 2025-1"), a $159.144 million consumer loan ABS transaction. Oportun 2025-1 is an amortizing ...